Ventripoint Diagnostics (TSXV:VPT; OTC:VPTDF) appointed Justin Leushner as CEO, replacing Dr. George Adams, who was elected chairman of the board.
Mr. Leushner, who was named president of Ventripoint in September, has a proven track record in the medical device sector, co-founding Sernova in 2004. He most recently was CEO of the Centre for Imaging Technology Commercialization.
In a statement, Ventripoint said Mr. Leushner’s “unique leadership experience in life sciences and biotechnology will help ensure the company’s future success.”
Dr. Adams said that with regulatory approvals received for the VMS+ 3.0 in Canada, Europe and the U.S., “I have accomplished my goal as CEO of leading the team to create the best cardiac analysis device in the market.”
Mr. Leushner said that working with the strong management and clinical team over the past few months, “it is clear that the company is now ready to achieve its full potential as we begin selling our new system to hospitals and cardiac centers worldwide.”
In addition to Mr. Leushner’s appointment, Danny Dalla-Longa stepped down as a director after more than a decade of service.